3.9 Article

Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin

Journal

INTERNATIONAL MEDICAL CASE REPORTS JOURNAL
Volume 14, Issue -, Pages 707-709

Publisher

DOVE MEDICAL PRESS LTD
DOI: 10.2147/IMCRJ.S324394

Keywords

anterior subcapsular cataract; enfortumab vedotin; urothelial carcinoma

Ask authors/readers for more resources

Enfortumab vedotin, an antibody-drug conjugate recently approved by the FDA for the treatment of urothelial cancer, was associated with the development of bilateral anterior subcapsular cataracts in a reported case. This adverse effect of cataract development had not been previously documented with the use of Enfortumab vedotin.
Enfortumab vedotin is an antibody-drug conjugate that was recently granted accelerated US Food and Drug Administration approval for the treatment of locally advanced or metastatic urothelial cancer. Early clinical trials identified blurry vision, increased lacri-mation and other events associated with dry eye as potential side effects. We report a case of bilateral anterior subcapsular cataract development following initiation of enfortumab vedo-tin. Enfortumab vedotin is not previously known to cause cataract development or progres-sion and, thus, our patient's presentation may reflect the first report of an undocumented adverse effect of this novel agent.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.9
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available